What was filed
Aurobindo Pharma Limited disclosed that its wholly owned subsidiary, Aurobindo Pharma USA, Inc., has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. According to the filing, the transaction is valued on a cash-free, debt-free basis and inclusive of normalized working capital, and is expected to close before the end of June 2026. The regulatory clearance removes the antitrust gating item ahead of completion.
What Aurobindo is acquiring
Lannett is described in the filing as a Pennsylvania-based generic pharmaceutical company focused on the development and commercialization of complex, non-opioid controlled substances. The company said the deal expands Aurobindo USA's offering in that segment and adds a U.S.-based manufacturing facility — a site in Seymour, Indiana — to its network. Per the filing, that site can scale production to roughly 4 billion doses annually, which the company framed as strengthening its domestic manufacturing footprint in line with U.S. supply-chain resilience priorities.
What the company says it expects
The filing states the company expects the transaction to be immediately accretive to Aurobindo Group's earnings per share, and to generate cost efficiencies, SG&A synergies and operational integration advantages. These are the company's own stated expectations, accompanied in the release by a standard forward-looking-statements disclaimer noting that actual results could differ. The release carries supporting comments from the chief executives of both Aurobindo Pharma USA and Lannett.